European Regulator Says Data Don't Confirm Risk From GLP-1 Diabetes Drugs

European Regulator Says Data Don't Confirm Risk From GLP-1 Diabetes Drugs

LONDON - The European Committee for Medicinal Products for Human Use (CHMP) said July 26 that a review of glucagon-like peptide 1 agonists (GLP-1s) and dipeptidylpeptidase-4 (DPP-4) inhibitors has concluded that current data do not confirm recent reports that the diabetes drugs carry an increased risk of pancreatic adverse events, such as pancreatitis and pancreatic cancer.

Find full version on lexis Advance®
Access this news story on lexis.com®